TABLE 1.
Clinical characteristics of lung transplant recipients who held and did not hold perivaccination antimetabolite therapy
| Overall (n = 35) | Non-AMT hold (n = 6) | AMT hold (n = 29) | |
|---|---|---|---|
| Age, median (IQR) | 56 (40–65) | 66 (45–71) | 49 (40–65) |
| Female sex, no. (%) | 20 (57) | 4 (67) | 16 (55) |
| Non-White, no. (%) | 5 (14) | 1 (17) | 4 (14) |
| Hispanic/Latino, no. (%) | 1 (3) | 1 (17) | 0 (0) |
| Diagnosis, no. (%) | |||
| CF/bronchiectasis | 12 (34) | 1 (17) | 11 (38) |
| ILD/IPF | 10 (29) | 2 (33) | 8 (28) |
| COPD/A1ATD | 4 (11) | 2 (33) | 2 (7) |
| PH/sarcoidosis/HP/BOd | 6 (17) | 1 (17) | 5 (17) |
| Other | 3 (9) | 0 (0) | 3 (10) |
| Medication included in immunosuppression regimen, no. (%) | |||
| Azathioprine | 6 (17) | 2 (33) | 4 (14) |
| Cyclosporine | 4 (11) | 1 (17) | 3 (10) |
| Everolimus | 2 (6) | 2 (33) | 0 (0) |
| Glucocorticoida | 35 (100) | 6 (100) | 29 (100) |
| Mycophenolate mofetil | 29 (83) | 4 (67) | 25 (86) |
| Tacrolimus | 30 (86) | 5 (83) | 26 (90) |
| Triple Immunosuppression, no. (%) | 33 (94) | 6 (100) | 27 (93) |
| Mycophenolate total daily dose (mg/d), median (IQR) | 1000 (360–1500) | 720 (0–1000) | 1000 (720–1500) |
| Glucocorticoid total daily dose >10 mg/d, no. (%) | 0 (0) | 0 (0) | 0 (0) |
| Years since transplant, median (IQR) | 4.4 (2.9–8.8) | 3.3 (2.5–8.3) | 4.9 (3.2, 8.8) |
| Days between D2 and D3, median (IQR) | 164 (146–188) | 148 (99–177) | 166 (150–188) |
| D3 vaccine type, no. (%) | |||
| BNT162b2 | 11 (31) | 2 (33) | 9 (31) |
| mRNA-1273 | 23 (66) | 3 (50) | 20 (69) |
| Ad26.COV2.S | 1 (3) | 1 (17) | 0 (0) |
| Preexisting positive increase DSA post-D3, no. (%)b,c | 1 (7) | 0 (0) | 1 (8) |
Glucocorticoid includes prednisone and prednisone equivalents.
The denominator differs from the total N as only 15 participants had pre- and post-D3 DSA.
Preexisting positive increase DSA post-D3 denotes that the patient had a positive HLA prior pre-D3 that was increased when measured post-D3.
A1ATD, alpha-1 antitrypsin deficiency; AMT, antimetabolite therapy; BO, bronchiolitis obliterans; CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; DSA, donor-specific antibody; HP, hypersensitivity pneumonitis; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; IQR, interquartile range; PH, pulmonary hypertension.